Keystone shows Gates the money

In our May issue, James Aiken, the CEO of the Keystone Symposia, linkurl:wrote that;http://www.the-scientist.com/article/display/23399/ ?the long reach of Bill Gates? had ?finally touched the Keystone Symposia, and all of conference planning, really.? Aiken was writing a grant proposal to the Foundation, and they required him to show measured value for the conferences. Aiken went on to describe a method for quantifying the conferences? impact. When he tallied the results of the instrument Keys

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
In our May issue, James Aiken, the CEO of the Keystone Symposia, linkurl:wrote that;http://www.the-scientist.com/article/display/23399/ ?the long reach of Bill Gates? had ?finally touched the Keystone Symposia, and all of conference planning, really.? Aiken was writing a grant proposal to the Foundation, and they required him to show measured value for the conferences. Aiken went on to describe a method for quantifying the conferences? impact. When he tallied the results of the instrument Keystone used, the results were impressive: ?Conservative extrapolation to the entire Keystone Symposia season of meetings would suggest that at least $20 to $30 million in research funds is diverted to more effective use each year because of information learned at our conferences,? Aiken wrote. Those results seem to have impressed the Gates Foundation, too, which just linkurl:gave Keystone a $2.6 million grant;http://www.keystonesymposia.org/News/ to expand its Global Health Series. According to the Foundation, the survey results were one of the key factors in the foundation's decision to continue supporting Keystone. For tips on how to apply to non-profits for grants to support your own research, keep an eye out for our November issue.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

  • Ivan Oransky

    This person does not yet have a bio.
Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo
Characterizing Immune Memory to COVID-19 Vaccination

Characterizing Immune Memory to COVID-19 Vaccination

10X Genomics
Optimize PCR assays with true linear temperature gradients

Applied Biosystems™ VeriFlex™ System: True Temperature Control for PCR Protocols

Thermo Fisher Logo

Products

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

iStock

Agilent BioTek Cytation C10 Confocal Imaging Reader

agilent technologies logo